Cancer dataset gets a boost
The Genomics of Drug Sensitivity in Cancer project recently released data from four years of work, a freely available data set that includes data comparing the responses of nearly 1,000 cancer cell lines to 453 licensed and experimental drugs. This dataset now offers information on 453 cancer treatment compounds, 989 cancer cell lines, 494,973 genomic associations tested and 386,293 drug dose response curves. Researchers from the Wellcome Sanger Institute and Massachusetts General Hospital led the project.
Mathew Garnett, co-lead of the project and group leader at the Wellcome Sanger Institute, said: “We are delighted that we have been able to create, and release, this valuable data to the global cancer research community. Our Genomics of Drug Sensitivity in Cancer database is the world’s largest repository for information on how a cancer’s underlying genomic landscape influences its response to cancer treatments. We hope it will provide new insights that will point to new ways to target and treat individual tumors.”